环磷酰胺-话题@MedSci

#环磷酰胺#

55篇内容 | 2051人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2210266, encodeId=9de022102663e, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a> <a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=8d82e952353' target=_blank style='color:#2F92EE;'>#网络药理学#</a> <a href='/topic/show?id=a56b1155967e' target=_blank style='color:#2F92EE;'>#化疗性脱发#</a> <a href='/topic/show?id=d81f11559ed9' target=_blank style='color:#2F92EE;'>#墨旱莲#</a>, objectTitle=J Ethnopharmacol：靶向p53/Fas通路的墨旱莲醚提取物治疗化疗性脱发的发现, objectType=article, longId=830444, objectId=d22483044486, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240616/1718526190459_5610093.jpg, objectUrl=/article/show_article.do?id=d22483044486, replyNumber=0, likeNumber=0, createdTime=7小时前, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d22483044486, moduleTitle=J Ethnopharmacol：靶向p53/Fas通路的墨旱莲醚提取物治疗化疗性脱发的发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22483044486)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2206051, encodeId=36472206051b3, content=<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a> <a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=52b3114e2126' target=_blank style='color:#2F92EE;'>#单倍型造血干细胞移植#</a>, objectTitle=【Cancer】成人AML单倍型移植GVHD预防：后置环磷酰胺对比ATG对比联用, objectType=article, longId=826949, objectId=8a0e826949e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240522/1716363924093_5579292.jpg, objectUrl=/article/show_article.do?id=8a0e826949e9, replyNumber=0, likeNumber=11, createdTime=2024-05-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8a0e826949e9, moduleTitle=【Cancer】成人AML单倍型移植GVHD预防：后置环磷酰胺对比ATG对比联用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a0e826949e9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201957, encodeId=d5b3220195ed6, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=54ba11414e8a' target=_blank style='color:#2F92EE;'>#黄芪皂苷III#</a>, objectTitle=“杀敌一千，自损八百”可被破局了！黄芪皂苷III可调节环磷酰胺所诱导的免疫抑制, objectType=article, longId=824505, objectId=e3da82450541, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240506/1714960322761_8538692.jpg, objectUrl=/article/show_article.do?id=e3da82450541, replyNumber=0, likeNumber=11, createdTime=2024-05-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e3da82450541, moduleTitle=“杀敌一千，自损八百”可被破局了！黄芪皂苷III可调节环磷酰胺所诱导的免疫抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3da82450541)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183216, encodeId=04c42183216ae, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=4bd8e16970e' target=_blank style='color:#2F92EE;'>#白消安#</a> <a href='/topic/show?id=bd06110403a7' target=_blank style='color:#2F92EE;'>#PI3K/AKT/FOXO3a信号通路#</a> <a href='/topic/show?id=23a0108402da' target=_blank style='color:#2F92EE;'>#卵巢储备减少#</a> <a href='/topic/show?id=a1671104045a' target=_blank style='color:#2F92EE;'>#温中补肾方#</a>, objectTitle=J Ethnopharmacol：基于网络药理学的温中补肾方改善小鼠卵巢储备功能下降的作用及机制研究, objectType=article, longId=810264, objectId=4b42810264b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240120/1705747063949_5610093.jpg, objectUrl=/article/show_article.do?id=4b42810264b0, replyNumber=0, likeNumber=42, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4b42810264b0, moduleTitle=J Ethnopharmacol：基于网络药理学的温中补肾方改善小鼠卵巢储备功能下降的作用及机制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b42810264b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178288, encodeId=7e5d21e8288e7, content=<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a> <a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=971388025d1' target=_blank style='color:#2F92EE;'>#获得性血友病A#</a>, objectTitle=AJH：单剂量利妥昔单抗联合糖皮质激素与环磷酰胺联合糖皮质激素治疗新诊断的获得性血友病A疗效比较, objectType=article, longId=807619, objectId=057b80e61966, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697393424174_4754896.jpeg, objectUrl=/article/show_article.do?id=057b80e61966, replyNumber=0, likeNumber=45, createdTime=2023-12-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=057b80e61966, moduleTitle=AJH：单剂量利妥昔单抗联合糖皮质激素与环磷酰胺联合糖皮质激素治疗新诊断的获得性血友病A疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=057b80e61966)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173004, encodeId=b0f621e3004d5, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=d1b4599159f' target=_blank style='color:#2F92EE;'>#普乐沙福#</a>, objectTitle=Haematologica：新药时代MM干细胞动员新方案：环磷酰胺、G-CSF和按需普乐沙福, objectType=article, longId=803295, objectId=b11e80329575, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668021819040_4754896.jpeg, objectUrl=/article/show_article.do?id=b11e80329575, replyNumber=0, likeNumber=40, createdTime=2023-12-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b11e80329575, moduleTitle=Haematologica：新药时代MM干细胞动员新方案：环磷酰胺、G-CSF和按需普乐沙福, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b11e80329575)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2161692, encodeId=44bd21616922d, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> , objectTitle=Arthritis Rheumatol：Rituximab和环磷酰胺在治疗抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)的长期安全性比较, objectType=article, longId=795208, objectId=4910e95208ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301008/1696774402490_5485250.jpg, objectUrl=/article/show_article.do?id=4910e95208ad, replyNumber=0, likeNumber=42, createdTime=2023-10-09, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4910e95208ad, moduleTitle=Arthritis Rheumatol：Rituximab和环磷酰胺在治疗抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)的长期安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4910e95208ad)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2124702, encodeId=13252124e0284, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>（TA）是一种罕见于儿童和婴儿的<a href='/topic/show?id=da4c4399516' target=_blank style='color:#2F92EE;'>#大血管血管炎#</a>。<a href='/topic/show?id=8eeb8e122c6' target=_blank style='color:#2F92EE;'>#英夫利昔单抗#</a>的完全缓解率最高（40%）。促使完全缓解的其他药物是<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>（40%）和<a href='/topic/show?id=674769813be' target=_blank style='color:#2F92EE;'>#甲氨蝶呤#</a>（38%）。58%的患者需要进行侵入性手术。最常见的并发症是<a href='/topic/show?id=e33a51591f8' target=_blank style='color:#2F92EE;'>#心脏病#</a>（50%）、<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>（42%）和严重感染（33%）。没有患者死亡。, objectTitle=Rheumatology：婴儿Takayasu，临床特征和长期结果, objectType=article, longId=751521, objectId=17b5e5152162, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221211/1670739228160_5610093.png, objectUrl=/article/show_article.do?id=17b5e5152162, replyNumber=0, likeNumber=86, createdTime=2023-04-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=17b5e5152162, moduleTitle=Rheumatology：婴儿Takayasu，临床特征和长期结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17b5e5152162)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=2089222, encodeId=20b6208922251, content=<a href='/topic/show?id=8c519053e85' target=_blank style='color:#2F92EE;'>#西罗莫司#</a>联合<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>治疗<a href='/topic/show?id=c7415985ead' target=_blank style='color:#2F92EE;'>#晚期肉瘤#</a>耐受良好 , objectTitle=西罗莫司联合环磷酰胺治疗晚期肉瘤耐受良好, objectType=article, longId=2773, objectId=df442e7348, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=df442e7348, replyNumber=0, likeNumber=65, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df442e7348, moduleTitle=西罗莫司联合环磷酰胺治疗晚期肉瘤耐受良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df442e7348)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2089214, encodeId=6afa20892144e, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>：<a href='/topic/show?id=377096965f6' target=_blank style='color:#2F92EE;'>#长春新碱#</a>-<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓扑替康#</a>-<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>用于非转移性<a href='/topic/show?id=f3934e272e8' target=_blank style='color:#2F92EE;'>#尤文氏肉瘤#</a>初始治疗的III期临床试验结果，<a href='/topic/show?id=5f394e273fd' target=_blank style='color:#2F92EE;'>#尤文肉瘤#</a> (EWS) 是一种罕见的<a href='/topic/show?id=5a03104e94f1' target=_blank style='color:#2F92EE;'>#儿童恶性肿瘤#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211017/1634453597626_2110107.JPG, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=94, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1284391, encodeId=56cf12843919f, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, objectType=article, longId=739393, objectId=dc53e393931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc53e393931b, replyNumber=0, likeNumber=72, createdTime=2022-09-17, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc53e393931b, moduleTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc53e393931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284390, encodeId=aa39128439029, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=Rheumatology：用低剂量环磷酰胺动员自体干细胞移植在系统性硬化患者中是可行的, objectType=article, longId=735968, objectId=8520e359680c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8520e359680c, replyNumber=0, likeNumber=76, createdTime=2022-08-17, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8520e359680c, moduleTitle=Rheumatology：用低剂量环磷酰胺动员自体干细胞移植在系统性硬化患者中是可行的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8520e359680c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284389, encodeId=31b112843893b, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, objectType=article, longId=728385, objectId=dc7ae283851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7ae283851f, replyNumber=0, likeNumber=78, createdTime=2022-06-02, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7ae283851f, moduleTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7ae283851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284388, encodeId=e0811284388e6, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析, objectType=article, longId=727292, objectId=474ce272928d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=474ce272928d, replyNumber=0, likeNumber=62, createdTime=2022-05-20, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=474ce272928d, moduleTitle=Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=474ce272928d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284387, encodeId=9efd128438e27, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=Transplant Cell Ther：移植后环磷酰胺治疗以及全骨髓和淋巴照射对缓解期 AML 患者的预处理方案测试, objectType=article, longId=724850, objectId=b900e2485061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b900e2485061, replyNumber=0, likeNumber=66, createdTime=2022-04-24, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b900e2485061, moduleTitle=Transplant Cell Ther：移植后环磷酰胺治疗以及全骨髓和淋巴照射对缓解期 AML 患者的预处理方案测试, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b900e2485061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284386, encodeId=044f128438676, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=AACR 2022：奥拉帕利联合环磷酰胺和二甲双胍在子宫内膜癌中表现良好（ENDOLA试验）, objectType=article, longId=724153, objectId=a609e241538d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a609e241538d, replyNumber=0, likeNumber=67, createdTime=2022-04-14, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a609e241538d, moduleTitle=AACR 2022：奥拉帕利联合环磷酰胺和二甲双胍在子宫内膜癌中表现良好（ENDOLA试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a609e241538d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284385, encodeId=1bd3128438548, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=Leukemia：口服沙利度胺-环磷酰胺-地塞米松治疗复发/难治性成人朗格汉斯细胞组织细胞增多症是有效且安全的方案, objectType=article, longId=723518, objectId=20a9e235180d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20a9e235180d, replyNumber=0, likeNumber=60, createdTime=2022-04-06, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20a9e235180d, moduleTitle=Leukemia：口服沙利度胺-环磷酰胺-地塞米松治疗复发/难治性成人朗格汉斯细胞组织细胞增多症是有效且安全的方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20a9e235180d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284384, encodeId=5d16128438431, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=Leukemia：骨髓纤维化患者使用半相合供体和移植后环磷酰胺进行同种异体血液或骨髓移植, objectType=article, longId=221787, objectId=a99e221e875f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a99e221e875f, replyNumber=0, likeNumber=69, createdTime=2021-12-11, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a99e221e875f, moduleTitle=Leukemia：骨髓纤维化患者使用半相合供体和移植后环磷酰胺进行同种异体血液或骨髓移植, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a99e221e875f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284383, encodeId=d4961284383a8, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, objectType=article, longId=221413, objectId=18d1221413ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d1221413ca, replyNumber=0, likeNumber=72, createdTime=2021-12-03, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d1221413ca, moduleTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d1221413ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1284382, encodeId=9350128438211, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, objectTitle=PB：槐杞黄颗粒减轻环磷酰胺诱导肾毒性的机制研究, objectType=article, longId=219329, objectId=e6732193291a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6732193291a, replyNumber=0, likeNumber=0, createdTime=2021-10-28, rootId=0, userName=waiwai3030, userId=07f7192, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6732193291a, moduleTitle=PB：槐杞黄颗粒减轻环磷酰胺诱导肾毒性的机制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6732193291a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

环磷酰胺

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#p53# #环磷酰胺# #网络药理学# #化疗性脱发# #墨旱莲#

J Ethnopharmacol：靶向p53/Fas通路的墨旱莲醚提取物治疗化疗性脱发的发现

7小时前发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#急性髓系白血病# #环磷酰胺# #单倍型造血干细胞移植#

【Cancer】成人AML单倍型移植GVHD预防：后置环磷酰胺对比ATG对比联用

2024-05-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#环磷酰胺# #黄芪皂苷III#

“杀敌一千，自损八百”可被破局了！黄芪皂苷III可调节环磷酰胺所诱导的免疫抑制

2024-05-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#环磷酰胺# #白消安# #PI3K/AKT/FOXO3a信号通路# #卵巢储备减少# #温中补肾方#

J Ethnopharmacol：基于网络药理学的温中补肾方改善小鼠卵巢储备功能下降的作用及机制研究

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#利妥昔单抗# #环磷酰胺# #获得性血友病A#

AJH：单剂量利妥昔单抗联合糖皮质激素与环磷酰胺联合糖皮质激素治疗新诊断的获得性血友病A疗效比较

2023-12-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #环磷酰胺# #普乐沙福#

Haematologica：新药时代MM干细胞动员新方案：环磷酰胺、G-CSF和按需普乐沙福

2023-12-05发表于上海

(审核中...)

前往app查看评论内容

#环磷酰胺#

Arthritis Rheumatol：Rituximab和环磷酰胺在治疗抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)的长期安全性比较

2023-10-09发表于上海

(审核中...)

前往app查看评论内容

全文收起 #Takayasu动脉炎#（TA）是一种罕见于儿童和婴儿的#大血管血管炎#。#英夫利昔单抗#的完全缓解率最高（40%）。促使完全缓解的其他药物是#环磷酰胺#（40%）和#甲氨蝶呤#（38%）。58%的患者需要进行侵入性手术。最常见的并发症是#心脏病#（50%）、#卒中#（42%）和严重感染（33%）。没有患者死亡。

Rheumatology：婴儿Takayasu，临床特征和长期结果

2023-04-10发表于上海

(审核中...)

前往app查看评论内容

#西罗莫司#联合#环磷酰胺#治疗#晚期肉瘤#耐受良好

西罗莫司联合环磷酰胺治疗晚期肉瘤耐受良好

2022-09-20

(审核中...)

前往app查看评论内容

#J Clin Oncol#：#长春新碱#-#拓扑替康#-#环磷酰胺#用于非转移性#尤文氏肉瘤#初始治疗的III期临床试验结果，#尤文肉瘤# (EWS) 是一种罕见的#儿童恶性肿瘤#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-09-20

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病

2022-09-17

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

Rheumatology：用低剂量环磷酰胺动员自体干细胞移植在系统性硬化患者中是可行的

2022-08-17

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验

2022-06-02

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析

2022-05-20

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

Transplant Cell Ther：移植后环磷酰胺治疗以及全骨髓和淋巴照射对缓解期 AML 患者的预处理方案测试

2022-04-24

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

AACR 2022：奥拉帕利联合环磷酰胺和二甲双胍在子宫内膜癌中表现良好（ENDOLA试验）

2022-04-14

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

Leukemia：口服沙利度胺-环磷酰胺-地塞米松治疗复发/难治性成人朗格汉斯细胞组织细胞增多症是有效且安全的方案

2022-04-06

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

Leukemia：骨髓纤维化患者使用半相合供体和移植后环磷酰胺进行同种异体血液或骨髓移植

2021-12-11

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效

2021-12-03

waiwai3030 (审核中...)

前往app查看评论内容

#环磷酰胺#

PB：槐杞黄颗粒减轻环磷酰胺诱导肾毒性的机制研究

2021-10-28

科室
- - 订阅+
  - 更多科室
工具
服务